Real‐world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study

Real‐world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study

Abstract Aims We aimed to determine the use of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real‐life setting. Methods Real‐world data on Empagliflozin and Dapagliflozin use in patients with HE...

Full description

Saved in:
Bibliographic Details
Main Authors: Umut Kocabas, Isil Ergin, Veysel Yavuz, Cihan Altın, Mehmet Kaplan, Gülsüm Meral Yılmaz Öztekin, Mustafa Doğduş, Selda Murat, Bektaş Murat, Tarık Kıvrak, Dilay Karabulut, Ersin Kaya, İbrahim Halil Özdemir, Cennet Yıldız, Fatma Özge Salkın, Emre Özçalık, Şeyda Günay Polatkan, Fahri Çakan, Taner Şen, Umut Karabulut, Sinem Çakal, Ersan Oflar, Ümit Yaşar Sinan, Mustafa Yenerçağ, Uğur Önsel Türk
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:ESC Heart Failure
Subjects:
guideline
heart failure
sodium–glucose cotransporter 2 inhibitors
Online Access:https://doi.org/10.1002/ehf2.15049
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ehf2.15049

Similar Items